Loading...
•
Dec 31, 2025
Lantheus Q4 2025 Earnings Report
Lantheus reported fourth quarter 2025 revenue growth with higher GAAP earnings, while adjusted profitability declined modestly year-over-year.
Key Takeaways
Fourth quarter 2025 worldwide revenue increased 4.0% to 406786000, GAAP net income was 54088000, and adjusted net income was 110669000, with strong cash generation during the quarter.
Worldwide revenue grew 4.0% year-over-year to 406786000.
GAAP net income was 54088000 compared to a loss in the prior year period.
Adjusted net income was 110669000, or 1.67 per diluted share.
Net cash provided by operating activities was 90178000 with free cash flow of 81390000.
Revenue by Segment
Forward Guidance
For full year 2026, Lantheus expects revenue between 1400000000 and 1450000000 and adjusted fully diluted EPS between 5.00 and 5.25.
Positive Outlook
- 2026 revenue guidance range of 1400000000 to 1450000000.
- 2026 adjusted fully diluted EPS guidance of 5.00 to 5.25.
- Strategic focus on innovative PET radiodiagnostics.
- Multiple anticipated FDA approvals in 2026.
- Strong balance sheet with 359121000 in cash at year end.
Challenges Ahead
- PYLARIFY sales declined 9.7% year-over-year in Q4.
- Adjusted net income decreased 4.1% year-over-year.
- Operating income declined 32.2% year-over-year.
- Significant cash outflows for acquisitions and share repurchases.
- Exposure to regulatory and reimbursement risks.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...